For the acute treatment of migraine in adults.
Important Safety Information
Prescribing Information
Stay Informed
Request a Representative
NOW AVAILABLE IN A 6-PACK

Migraine relief when your patients need it the most

Exploratory endpoints and post hoc analyses of patient-reported efficacy data for some patients showed the following results.4*

Prescribe Trudhesa

Rapid.

Pain relief can start in as few as 15 minutes.4

Learn More →

Sustained.

Pain freedom lasted two days with one dose.4

Learn More →

Consistent.

Results delivered time after time.3

Learn More →

Even late in an attack.

Pain freedom on their terms, even when taken late into a migraine attack.4-6

Learn More →

*Based on the phase 3, open-label safety study that enrolled 360 patients with migraine, which assessed safety, tolerability, and exploratory efficacy of Trudhesa.4

How many migraine days per month are your patients STILL having?
Prescribe Trudhesa

How many migraine days per month are your patients STILL having?

Create a comprehensive treatment plan with Trudhesa. Learn how Trudhesa delivers relief by sending medication to the upper nasal space and how you can prescribe Trudhesa as an add-on for your patients already using a gepant.2,3
poster
4 min
Chapter 1:
The Trudhesa Patient
Now Playing
3 min
Chapter 2:
Trudhesa Safety
Now Playing
4 min
Chapter 3:
Trudhesa Efficacy
Now Playing
2 min
Chapter 4:
POD® Technology
Now Playing
2 min
Chapter 5:
Prescribing Trudhesa
Now Playing
Prescribe Trudhesa

References: 1. Saper JR, Silberstein S, Dodick D, Rapoport A. DHE in the pharmacotherapy of migraine: potential for a larger role. Headache. 2006;46(suppl 4):S212-S220. 2. Trudhesa. Prescribing information. Impel Pharmaceuticals; 2021. 3. Shrewsbury SB, Jeleva M, Satterly KH, Lickliter J, Hoekman J. STOP 101: a phase 1, randomized, open-label, comparative bioavailability study of INP104, dihydroergotamine mesylate (DHE) administered intranasally by a I123 Precision Olfactory Delivery (POD®) Device, in healthy adult subjects. Headache. 2019;59(3):394-409. 4. Smith TR, Winner P, Aurora SK, Jeleva M, Hocevar-Trnka J, Shrewsbury SB. STOP 301: a phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD®) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients. Headache. 2021;61(8):1214-1226. 5. Aurora SK, Ray S, Satterly K, Shrewsbury SB, Hoekman J. Does dihydroergotamine treat the “whole migraine”? Poster presented at: American Headache Society Virtual Annual Scientific Meeting, June 2020. 6. Data on File. Impel Pharmaceuticals. 2020.

For US Healthcare Professionals Only

You are about to enter a site that is for US healthcare professionals (HCPs) only.

By continuing, you certify that you are a healthcare professional and that you wish to proceed to the healthcare professional’s section of this site. Products or treatments described on this site are available in the US but may not be available in other countries.

I am an HCP

I am not an HCP

Now Available

Trudhesa is now available in a 6-count box.

Prescribing stays the same.

E-prescribe through ASPN or Phil Pharmacies*

* Not available through retail pharmacies. Visit TrudhesaHCP.com/prescribe to learn more.